chartexchange

Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

GlobeNewswire Inc. | Nov 17, 2026 6:00 AM EST

STAFFORD, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that two abstracts have been accepted for publication at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2026 along with two corresponding poster presentations.

Read original article